Brief: Destiny Pharma Evaluates All Options To Achieve Maximum Value For XF-73 Nasal Asset
04/01/2024 07:31
Jan 4 (Reuters) - Destiny Pharma PLC DEST.L :
* YEAR END BUSINESS UPDATE
* EVALUATING ALL OPTIONS TO ACHIEVE MAXIMUM VALUE FOR XF-73
NASAL
ASSET
* COMPANY IS FUNDED THROUGH TO Q1 2025, ALLOWING IT TO
DELIVER ON
ITS CURRENT PLANNED ACTIVITIES
Source text for Eikon: ID:nRSD5868Ya
Further company coverage: DEST.L
((Reuters.Briefs@thomsonreuters.com;))